![Martin Babler](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Martin Babler
Vorstandsvorsitzender bei
ALUMIS INC.
Vermögen: 3 Mio $ am 30.06.2026
Profil
Currently, Martin Babler is Chairman, President & Chief Executive Officer at Alumis, Inc. since 2021.
He is Director-Emerging Companies Section at Biotechnology Innovation Organization.
He serves as Independent Director at Prelude Therapeutics, Inc. since 2021, Omega Alpha SPAC since 2020, and MapLight Therapeutics, Inc. starting in 2026.
Formerly, Mr. Babler was President & Chief Executive Officer at Talima Therapeutics, Inc. from 2007 to 2011.
He was President, Chief Executive Officer & Director at Principia Biopharma, Inc. from 2019 to 2020.
He was Independent Director at ZS Pharma, Inc. in 2015, Infinity Pharmaceuticals, Inc. from 2011 to 2014, and Neoleukin Therapeutics, Inc. He was Independent Director at 89bio, Inc. from 2024 to 2025 and Director at Sardona Therapeutics, Inc. from 2021 to 2025.
He was Vice President-Immunology Sales & Marketing at Genentech, Inc. from 2006 to 2007 and Principal at Eli Lilly & Co. from 1991 to 1998.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ALUMIS INC. 0,09 % | 05.05.2026 | 110.491 ( 0,09 % ) | 3 Mio $ | 30.06.2026 |
| 09.06.2026 | 0 ( -.--% ) | - $ | 30.06.2026 |
Aktive Positionen von Martin Babler
| Unternehmen | Position | Beginn |
|---|---|---|
| OMEGA ALPHA SPAC | Direktor/Vorstandsmitglied | 01.09.2020 |
| PRELUDE THERAPEUTICS INCORPORATED | Direktor/Vorstandsmitglied | 19.07.2021 |
| ALUMIS INC. | Vorstandsvorsitzender | 23.09.2021 |
| MAPLIGHT THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 23.06.2026 |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology advocacy organization representing biotech companies, industry leaders and state biotech associations | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Martin Babler
| Unternehmen | Position | Ende |
|---|---|---|
| 89BIO, INC. | Direktor/Vorstandsmitglied | 30.10.2025 |
Sardona Therapeutics, Inc.
 Sardona Therapeutics, Inc. Medical/Nursing ServicesHealth Services Provides cancer therapy services | Direktor/Vorstandsmitglied | 01.05.2025 |
| PRINCIPIA BIOPHARMA INC. | Vorstandsvorsitzender | 01.11.2020 |
| ZS PHARMA INC | Direktor/Vorstandsmitglied | 17.12.2015 |
| ░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
72
Beziehungen ersten Grades
14
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 14 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Eli Lilly & Co.
 Eli Lilly & Co. Pharmaceuticals: MajorHealth Technology Manufactures, wholesales and markets pharmaceutical products | Health Technology |
Talima Therapeutics, Inc.
 Talima Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops drug delivery systems | Health Technology |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology advocacy organization representing biotech companies, industry leaders and state biotech associations | Commercial Services |
ZS Pharma, Inc.
 ZS Pharma, Inc. BiotechnologyHealth Technology Develops develop new treatments of kidney and liver diseases | Health Technology |
Principia Biopharma, Inc.
 Principia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a R&D driven and AI-powered biopharma company | Health Technology |
Infinity Pharmaceuticals, Inc.
 Infinity Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops medicines for the treatment of cancer | Health Technology |
Prelude Therapeutics, Inc.
 Prelude Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops medicines targeting chromatin function to treat cancer and rare diseases | Health Technology |
89bio, Inc.
 89bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
MapLight Therapeutics, Inc.
 MapLight Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops therapeutics for debilitating central nervous system disorders | Health Technology |
Neoleukin Therapeutics, Inc.
 Neoleukin Therapeutics, Inc. BiotechnologyHealth Technology Develops de novo – therapeutic proteins to treat serious immunological disorders, including cancer and autoimmunity | Health Technology |
Omega Alpha SPAC
 Omega Alpha SPAC Financial ConglomeratesFinance Operates as a blank check company | Finance |
Alumis, Inc.
 Alumis, Inc. Pharmaceuticals: MajorHealth Technology Engages in research and development of medicines for autoimmune disorders | Health Technology |
Sardona Therapeutics, Inc.
Sardona Therapeutics, Inc. Medical/Nursing ServicesHealth Services Provides cancer therapy services | Health Services |
